Arcturus Therapeutics Provides Mid-Year Updates For ARCT-810, Ornithine Transcarbamylase Deficiency And Cystic Fibrosis Programs
Arcturus Therapeutics Provides Mid-Year Updates For ARCT-810, Ornithine Transcarbamylase Deficiency And Cystic Fibrosis Programs
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year
ARCT-810第二階段研究已在歐洲完成0.3mg/kg劑量水平的招募，預計今年晚些時候公佈數據。
ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease
ARCT-810將擴大第二階段臨床計劃，招募病情更嚴重的患者。
ARCT-032 IND for Phase 2 multiple ascending dose study to be submitted in the next 60 days
ARCT-032的第二階段多劑量上升研究的IND將在接下來的60天內提交。
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today is providing mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, an investigational inhaled mRNA therapeutic to treat cystic fibrosis (CF).
Arcturus Therapeutics Holdings Inc.(以下簡稱“公司”、“Arcturus ”，納斯達克股票代碼：ARCT)是一家全球信使RNA藥物公司，致力於開發用於治療肝臟和呼吸系統中未滿足醫療需求的感染性疾病和罕見疾病的疫苗和藥物，今天爲ARCT-810和ARCT-032提供年中更新。ARCT-810 是一種用於治療鳥氨酸轉移酶缺乏症的mRNA治療藥物，而ARCT-032是一種用於治療囊性纖維化的mRNA治療藥物。
譯文內容由第三人軟體翻譯。